chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Urticaria, pruritus and injection site pain, night sweats. Cephalexin.
Localized chronic urticaria on cheeks. It comes and goes. It tingles when it?s about to flare.  It?s not gone yet, even after trying several treatments given by different specialists.
Patient was given .25ml of Moderna Bivalent Booster instead of .5ml on 9/2/2022. She was contacted the following afternoon, 9/3/2022, to come back to pharmacy for revaccination. During the course of the conversation, she said she had the typical sore arm that patients experience post vaccination. It was unclear as to whether she was going to return despite explaining the importance of a full booster dose.
Tingling from fingertips to lower neck for a few hours after vaccine followed by pain from elbow to neck. Pain still occurring day after. Injection was given unusually high (above the crease of shoulder) and I am thinking that may be the reasoning for the unusual pain and tingling.
8 patients given expired vaccine; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (8 patients given expired vaccine) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030H21B) for COVID-19 vaccination.     The patient did not have any immediate allergies reaction to any vaccine, injection or shot or to any component of the COVID-19 vaccine, or a severe allergic reaction (anaphylaxis). The patient never diagnosed with cancer, leukemia, HIV/AIDS or any other condition that weakens the immune system, bleeding disorder, blood clots, myocarditis or pericarditis. .    On 13-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 25-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (8 patients given expired vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (8 patients given expired vaccine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No temperature excursions were noted at any time during the administration of the vaccine. No treatment medication were provided.   This case was linked to MOD-2022-530317, MOD-2022-531901 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 31-Mar-2022: Follow-up document received contains significant information: patient details and vaccine details updated.
Injection was administered somewhat posteriorly to the intended site possibly missing the deltoid.  In the following days, she had a bit of pain both at the time of the injection and for the next couple of days, but this has resolved. Also, after the 2nd shot, she developed what we recognize as typical post-vaccine symptoms fatigue, headache. This too resolved after a couple of days.
GOT THE 1ST VACCINE / I SWEAR I HAVE THE SHINGLES NOW / FEELING ON MY LOWER BACK; This case was reported by a pharmacist and described the occurrence of shingles in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th December 2020, the patient received the 1st dose of Shingrix. In December 2020, less than a week after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not repored. The age group of the patient was not reported but selcted as an adult as per vaccine indication. The reporter stated that, received 1st dose on wednesday and had shingles on the lower back. The reporter asked if should receive acyclovir.
Initial and follow-up information has been received from a health care worker and a medical assistant concerning a 44 year old, white female with no drug reactions, with seasonal allergies, whose reported weight was 152 pounds, who on 29-AUG-2006 at her annual physical with reportedly no illness was vaccinated subcutaneously, in the left upper arm with a 0.5 ml dose of Pneumovax 23. Concomitant therapy included ibuprofen and ALLEGRA, as needed. Subsequently the patient developed a red, raised, feverish area approximately 2 1/2 inches wide to her left upper arm. It was reported the patient ran a fever and felt nauseous times 2 days. The physician was informed. The patient sought unspecified medical attention. The patient was told to take ibuprofen, and instructed to apply ice to the affected area an if "resp" issues occurs. At the time of the report, the patient recovered. Additional information has been requested.
pt felt fain & pale p/vax;blood work;VS assessed by MD stat 225PM; 235PM asymptomatic;
After 7 days started itching, now big red swollen lump on injection site. Neck itching .
Patient received an additional dose of the Shingrix vaccine by mistake when he had already completed the series in 05/2022. Patient has not experienced any additional adverse effects since the administration of the vaccine on 09/06/2022.
Took second dose of Vivotif one day late; Spontaneous report received on 08JUL2020.  A pharmacist reported that a female consumer "took second dose of Vivotif one day late" (PT: Inappropriate schedule of product administration). She was receiving Vivotif for immunisation. On an unknown date, the consumer started Vivotif. She took her second dose of Vivotif one day late. It was reported that she did not know when she took the dose but it was in Jun 2020. Moreover, it was reported that the vaccine was left unrefrigerated at unknown room temperature for 3 hours, 5 hours, 8 hours and according to the temperature excursion, the vaccine was still good to use. Action taken with Vivotif with respect to the reported event was not applicable. The outcome of the reported event was unknown.  Company Comment: A consumer took second dose of Vivotif one day late (Inappropriate schedule of product administration). Vivotif dose should be taken every other day, and the causality of  inappropriate schedule of product administration is assessed as not applicable to Vivotif.; Sender's Comments: A consumer took second dose of Vivotif one day late (inappropriate schedule of product administration) and she also consumed Vivotif dose after it was left unrefrigerated at unknown room temperature for 3 hours, 5 hours, 8 hours (product storage error). Vivotif dose should be taken every other day and Vivotif should be stored in the refrigerator at the recommended temperatures. The causality of  inappropriate schedule of product administration and product storage error is assessed as not applicable to Vivotif.
Itchy, red, hot and painful to the touch vaccination site. Hurt so much that my clothing hurt the site. Felt like a terribly tender bruise. As the days went by up to day 11 post vaccine, the site increased in size of lump, heat, redness and itchiness., but the painful bruised feeling lessened slightly. It was at its biggest size, about a baseball, on day 11, but by day 14 all symptoms had resolved. No treatment administered.
Patient presented to the ED and was subsequently hospitalized for hyponatremia, orthostatic hypotension within 6 weeks of receiving covid vaccination.
Patient reported feeling pain and eventual numbness and loss of strength in left arm.  This began after the vaccination.  Patient contacted her Family Doctor.  Patient then saw her pain doctor,  who ordered Physical Therapy.  Patient is currently receiving PT twice weekly.
next day p/vax tired, malaise;sx still occurring 5 days later tired, malaise;
Rash starting6/23 on torso and upper body, no rash on legs. Itching, up to 50 lesion on body with new lesion occur daily. Given ZYRTEC to help with itching.
On 6 April 2015 (catch-up immunization due to lost medical coverage) patient received his first MMR and varicella vaccine in the form of PROQUAD (manufacturer Merck; Lot number K019100; 0.5 mL right thigh subcutaneously) as well as hepatitis a #1 (manufacturer Smithkline; Lot # 5CK4Y; 0.5 mL intramuscularly to the left thigh). Patient with no immediate adverse reactions. However, within one hour mother describes patient developing facial swelling to include periorbital edema and mild lip swelling as well as periorbital erythema and conjunctival injection. She specifically denies patient developing any tongue swelling, throat tightness, or any airway or vascular compromise. No associated generalize urticaria. No associated nausea, vomiting, or diarrhea. Mother denies patient with any other previous adverse reaction to vaccines. No known food allergies, or history of atopy such as asthma or eczema.
Acute disseminated encephalomyelitis about 1 week after shot. Fever started. Extreme irritability and screaming. Altered state of consciousness 12 days after. ADEM diagnosed 14 days after, shot and high-dose steroids given.  5/11/09 hospital records received for DOS 12/14/08-1/6/09. FINAL DIAGNOSIS: Acute Disseminated Encephalomyelitis Transferred from another hospital. Altered mental status, quiet whine. Fever, downward gaze with vertical nystagmus. Subsequently intubated for respiratory distress and stridor. Impaired movement of extremities. Stiffening right side of body. Seizures.
mild loss of proprioception in left hand; dissociation; administration_date:20May2021 10:00AM; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 23 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 20May2021 10:00 (Batch/Lot number: unknown) at the age of 23 years as dose 2, single for covid-19 immunization. The patient's relevant medical history was not reported. Concomitant medication(s) included: CRYSELLE. Past drug history included: Hep b vaccine, reaction(s): "known allergies ", notes: known allergies: Hep B vaccine. Vaccination history included: Bnt162b2 (1st dose, administration date=06May2021,, administration time=09:30 AM,, vaccine location=Left arm}, adverse event: Dissociation for 30 minutes on first dose, which cleared up.), administration date: 06May2021, when the patient was 23 years old, for COVID-19 immunization , reaction(s): "Dissociation". The following information was reported: LOSS OF PROPRIOCEPTION (non-serious) with onset 20May2021 12:00, outcome "unknown", described as "mild loss of proprioception in left hand"; DISSOCIATION (non-serious) with onset 20May2021 12:00, outcome "unknown", described as "dissociation"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 20May2021 10:00, outcome "unknown", described as "administration date:20May2021 10:00AM". Therapeutic measures were not taken as a result of loss of proprioception, dissociation.  Additional Information: Covid prior vaccination was unknown and Covid not tested post vaccination. Reason why batch/lot is Unknown: Misplaced/discarded. Facility where the most recent COVID-19 vaccine was administered was Pharmacy or Drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Medications the patient received within 2 weeks of vaccination:Cryselle Birth Control. Prior to vaccination, the patient diagnosed with COVID-19 was unknown. Since the vaccination, the patient has not been tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Complaint of feeling like her left arm was asleep and it was traveling up to her neck.  This progressed to feeling like there was a lump in her throat after the initial onset (about 30 minutes post vaccine).  Denied shortness of breath, difficulty swallowing or other symptoms.  Was provided with 25 mg benadryl IV at onset of throat concern.  Symptoms subsided and were almost 100% gone after 30 minutes post benadryl.
The unspecified patient experienced "fever" and "rash" that "could be chickenpox".; The unspecified patient experienced "fever" and "rash" that "could be chickenpox".; The unspecified patient experienced "fever" and "rash" that "could be chickenpox".; This spontaneous report was received from a nurse, referring to a child patient between 1 and 2-year-old of an unknown gender. The patient's pertinent medical history, previous drug reactions, allergies, or concomitant medications were unknown by the reporter.  On an unspecified date, the child was vaccinated with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (rHA) (PROQUAD) injection, 1 dose administered subcutaneously, as "routine vaccination" (lot number S027459 which has been verified to be valid, expiration date reported and validated as 02-MAR-2021) (vaccination scheme and anatomical site of injection were not reported).  On an unspecified date (also reported as "within 1-10 days of administration"), the patient experienced fever (pyrexia) and rash. According to the nurse, it could be chickenpox (varicella). The patient sought medical attention, however, no treatment was given for the events and the patient did not have any laboratory diagnostics or studies performed.   The outcome of the events pyrexia, rash and varicella was reported as recovered. The causal relationship between the aforementioned events and therapy with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (rHA) (PROQUAD) was not reported.   This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2007USA001873: US-009507513-2007USA001874: US-009507513-2007USA001872:
Patient has not experienced an adverse event. Patient got the Pfizer COVID vaccine after intentionally witholding information of a previous COVID vaccine (Johnson & Johnson). Information of previous COVID administration was obtained while billing the Pfizer vaccine administration through his insurance. He said he decided to get it because he heard Dr. on TV saying a booster vaccination may be required after getting the J & J vaccine.
Pt recvd pneumococcal vax 12NOV91 & exp swelling of the arm & an unspecified local rxn; pt was seen by MD;
Dizzy, sweating, chest tightness, impaired vision/ hearing, SOB, pale, Syncope
lump; ymph node that is swelling; A spontaneous report was received from a Healthcare Professional Dear concerning a 40-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events a lump, (lump) kind of swelling under her collar bond near her on left shoulder.she is assuming is it her, little hard to touch.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 26 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot batch: 012L20A) intramuscularly for prophylaxis of COVID-19 infection.  On 27 Jan 2021, the patient experienced the events a lump. (lump) kind of swelling under her collar bond near her on left shoulder. She is assuming is it her, little hard to touch.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   On an unknown date the outcome of events include, a lump, (lump) kind of swelling under her collar bond near her on left shoulder. she is assuming is it her, little hard to touch was not reported.  Based on comment Lump is coded as Subclavicular lymphadenopathy
Vaccine was given to a child that was under the approved age; This case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 2-year-old female patient who received DTPa-IPV (Kinrix) (batch number D24G7, expiry date 4th June 2022) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 1st June 2021, the patient received Kinrix (intramuscular) .5 ml and Kinrix Pre-Filled Syringe Device. On 1st June 2021, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows:  The reporter mentioned that a vaccine was given to a child that was under the approved age for the Kinrix vaccine. The patient with age 2 years, 1 month and 7 days old received Kinrix vaccine, which led to inappropriate age at vaccine administration. No other adverse events were reported for the patient. The reporter consented to follow-up.
Vomited 3 times: 3 am, 8 am and 12:30 pm.
8/7 Severe hives all over body, Occure during early am hrs, Seen by family PC on 08/07, Prednisone, Benadryl
Patient is immunocompromised and did not received a third dose but a booster dose; This spontaneous case was reported by a consumer and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient is immunocompromise and did not received a third dose but a booster dose) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022c21a, 006m20a and 038k20a) for COVID-19 vaccination.     The patient's past medical history included Cancer and Chemotherapy. Concurrent medical conditions included Immunocompromised.   On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Sep-2021, the patient experienced ACCIDENTAL UNDERDOSE (Patient is immunocompromise and did not received a third dose but a booster dose). At the time of the report, ACCIDENTAL UNDERDOSE (Patient is immunocompromise and did not received a third dose but a booster dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported No treatment drugs were reported
Narrative: Working Dx is 44 yr old M with recent secondery reaction from seecond dose of Moderna covicd vaccine with acute myocarditis with no coronary artery disease in hx and risk factors of hypertension( newly diagnosed) and hyperlipidemia with still complaints of exertional SOB. Hus lung examination is clear now . He had CT with contrast in the hospital and had no pulmonary embolism. It appears to me that his underlying asthma is causing breathing problem and he might getting worsening of symptoms from metoprolol.
This case was reported by a pharmacist via call center representative and described the occurrence of dizziness in a 30-year-old female patient who received HAVRIX adult (batch number 7439F, expiry date 20th February 2020). Concomitant products included TYPHIM. On 25th August 2017, the patient received HAVRIX adult. On 25th August 2017, immediately after receiving HAVRIX adult, the patient experienced dizziness, fainting, increased blood pressure, sweating, pallor and cyanosis. On 25th August 2017, the outcome of the dizziness, fainting, increased blood pressure, sweating, pallor and cyanosis were recovered/resolved. The reporter considered the dizziness, fainting, increased blood pressure, sweating, pallor and cyanosis to be related to HAVRIX adult. Additional details were provided as follows: The patient's concomitant products included non-GSK vaccine TYPHIM (batch number N1C1S, expiry date 15th March 2019). The patient received HAVRIX adult vaccine in left deltoid and experienced the side effects immediately following the administration on the HAVRIX in the left deltoid. Her head dropped to the back of the chair and her face was pale and also blue. The patient was sweating, described it as fainting but she was not unconscious that lasted for 5 to 10 minutes. The patient's blood pressure 5 minutes after vaccinating checked that read 129/114. It was checked again after 10 minutes and read as 115/77. The patient was asked to stay for 20 minutes and she was recovered when she left the pharmacy. The patient was again contacted by the reporter in the evening and she was fine. On 28th August 2017, the reporter again contacted the patient and she was fine.
Systemic: Dizziness / Lightheadness-Mild, Systemic: "passed out" but was never unresponsive - said he felt very faint while sitting in the observation chair-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: BP and HR were normal for pt. - he laid on the floor for ~10-15 minutes and then stayed seated for additional time and had someone come pick him up as he didn't feel comfortable driving. He stated he hadn't eaten anything this mornign before coming to recieve the immunization - he felt fine by the time he left and we checked in with him later in the day and he was still feeling fine
Pt recvd 1st dose of Hep B vax on 20SEP90 & exp pain in lt arm as well as stiffness in shoulder; pt presented to orthopedic surgeon & pt tx PT; dx w/frozen joint in shouler from lack of use; pt recovered;
OVER ALL BLECH FEELING; SORE ARM; GENERAL MALAISE; MINOR ACHES IN JOINTS; STUBBORN HEADACHE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient was previously treated with for prophylactic vaccination. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported 13:00 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced over all blech feeling, sore arm, general malaise, minor aches in joints, and stubborn headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from stubborn headache, general malaise, over all blech feeling, minor aches in joints, and sore arm. This report was non-serious.
Moderna COVID-19 Vaccine EUA was given to the left arm on 3/11/21.  Developed a mild/moderate rash on the left forearm on 03/16/21, which was 5 days after the shot was administered.  Started treating it with topical Hydrocortisone cream on 3/16/21.  By the next day 3/17/21, the rash looked much better (mild), but is still visible.
Patient received 0.2ml of undiluted Pfizer vaccine for 5-11 years
THIS INDIVIDUAL WAS SUPPOSED TO GET BIVALENT BOOSTER, INSTEAD WAS GIVEN PFIZER ADOLESCENT DOSE 0.3ML IM.
FEW MINUTES AFTER VACCINE PATIENT STATED SHE FELT HOT , THAT THE ARMS HAS A BURNING SENSATION, SHE WAS ALSO COLD AND SHAKING. BLOOD PRESSURE HIGH ( 911 WAS CALLED PT REFUSED TO GO TO THE HOSPITAL). WE KEPT  HER IN OBSERVATION WITH EMS ONSITE, AFTER MORE THAN ONE HOUR SHE  COMPLAINED OF CHEST PAIN, TRANSFERRED TO ER VIA AMBULANCE.
The symptoms started the day of the 2nd vaccine dose.  The pain has NOT changed since the vaccine shot. The person administered the shot, injected the needle at the top of my shoulder, not in the muscle, like the person did with the 1st vaccine dose.  My arm was sore after the 1st dose but went away after a couple of days.  but now, I have pain in the area of the shot, it is painful to the touch.  I have trouble sleeping in my left side, of my body, at night.  I have pain going down my arm when I lie down.  My arm is weak and can not lift normal things with it. I am VERY concerned that this pain will never go away and I have to live with it the rest of my life.